Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD versus high-dose melphalan plus stem cell transplant in newly diagnosed multiple myeloma
2008-008599-15Phase 3Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide, cyclophosphamide, dexamethasone and melphalan in multiple myeloma (MM) (2 arms), sponsored by Fondazione EMN Italy. Primary endpoint: Progression-free survival. Started Jul 2009; status: completed.
02
Drugs
lenalidomidecyclophosphamidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-008599-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008599-15.